Observational study on the effects of anti-obesity medications
Observational Study of Patients Being Treated With Anti-obesity Medication
This study is testing how well the obesity medications semaglutide and tirzepatide work for adults trying to lose weight, by looking at their body changes and lifestyle habits during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Texas Tech University Academic / other |
| Locations | 1 site (Lubbock, Texas) |
| Trial ID | NCT06790160 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the real-world effects of selected obesity medications, specifically semaglutide and tirzepatide, in adults undergoing medical weight management. Participants will undergo periodic testing for body composition and muscular performance, while also completing online surveys regarding their nutritional intake and physical activity. The study will evaluate changes in clinical markers and how lifestyle factors influence these outcomes over the course of treatment. By focusing on real-world data, the study seeks to provide insights that controlled trials may not capture.
Who should consider this trial
Good fit: Ideal candidates are adults beginning treatment with semaglutide or tirzepatide for obesity management and living near a DXA testing facility.
Not a fit: Patients with type 2 diabetes, those unwilling or unable to complete the study assessments, and pregnant individuals may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of anti-obesity medications in real-world settings, potentially improving treatment strategies for obesity.
How similar studies have performed: While there have been controlled trials on these medications, this observational approach is novel in evaluating their real-world effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity. * Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing. Exclusion Criteria: * Patients with type 2 diabetes. * Patients who report not being willing or able to complete the assessments included in this research study. * Patients who are currently pregnant or trying to become pregnant.
Where this trial is running
Lubbock, Texas
- Texas Tech University — Lubbock, Texas, United States (Recruiting)
Study contacts
- Study coordinator: Grant Tinsley, Ph.D.
- Email: grant.tinsley@ttu.edu
- Phone: 806-834-5895
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.